Antithrombin as a marker of severe acute hepatitis B
- 43 Downloads
Acute hepatitis B (AHB) can run a severe course, which sometimes leads to a fulminant disease with acute liver failure (ALF). Pro-coagulation factors are well-established markers of AHB severity, but less is known about the levels of anti-coagulation parameters in AHB.
In this study, we demonstrate that antithrombin (AT) plasma levels were associated with AHB severity in 161 patients.
Nine (6%) patients had severe AHB (i.e. international normalized ratio [INR] ≥ 1.6 and total bilirubin ≥ 10 mg/dL). Coagulopathy (i.e. INR > 1.2 and/or AT < 80%) was observed in 65 (40%) AHB patients on admission. Low initial plasma AT levels (i.e. < 80%) were observed in 56 (35%) patients. In all, plasma AT levels decreased in 91 (57%) patients during their hospital stay. Both baseline and nadir AT levels were significantly lower in severe than in mild and moderate AHB. Moreover, the concentration of AT negatively correlated with INR, aspartate aminotransferase, and total and conjugated bilirubin levels. Interestingly, nadir AT levels positively correlated with the duration of hospitalization.
These results indicate that plasma AT levels can be used as an additional marker of AHB severity.
KeywordsAcute hepatitis B Antithrombin Coagulopathy Severity
The study was supported by a project PROGRESS Q26-7 and UNCE 204022.
Compliance with ethical standards
Conflict of interest
SA, OB, PC, MK, and MH declare that they have no conflict of interest.
The authors declare that the study was performed in a manner conforming to the Helsinki declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.
The authors are solely responsible for the data and the content of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, or the printer/publishers are responsible for the results/findings and content of this article.
- 1.Choi HJ, Ko SY, Choe WH, et al. Clinical features of acute viral hepatitis B in Korea: a multi-center study. Korean J Hepatol. 2011;17:307–12.Google Scholar
- 2.Ay P, Torunoglu MA, Com S, et al. Trends of hepatitis B notification rates in Turkey, 1990 to 2012. Euro Surveill. 2013;18:20636.Google Scholar
- 3.Wilkins T, Zimmerman D, Schade RR. Hepatitis B: diagnosis and treatment. Am Fam Physician. 2010;81:965–72.Google Scholar
- 5.Thibault V, Laperche S, Thiers V, et al. Molecular epidemiology and clinical characteristics of hepatitis B identified through the French mandatory notification system. PLoS One. 2013;8:e75267.Google Scholar
- 11.Liang TJ, Hepatitis B. The virus and disease. Hepatology. 2009;495 Suppl:S13–21.Google Scholar
- 13.Chalupa P, Holub M. Favorable outcome of severe acute hepatitis B in a patient treated with antithrombin III and antiviral therapy. Clin Infect Dis. 2009;49:481.Google Scholar
- 15.Mueller MM, Bomke B, Seifried E. Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases. Thromb Res. 2002;107Suppl 1:S9–17.Google Scholar
- 16.Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869–78.Google Scholar
- 17.Nakahara K, Okuse C, Adachi S, et al. Use of antithrombin and thrombomodulin in the management of disseminated intravascular coagulation in patients with acute cholangitis. Gut Liver. 2013;7:363–70.Google Scholar
- 19.Hughes RD, Wendon J, Gimson AE. Acute liver failure. Gut. 1991;32Suppl:S86–91.Google Scholar
- 23.Isik S, Tuncyurek P, Zengin NI, et al. Antithrombin prevents apoptosis by regulating inflammation in the liver in a model of cold ischemia/warm reperfusion injury. Hepatogastroenterology. 2012;59:453–7.Google Scholar
- 24.Afshari A, Wetterslev J, Brok J, Moller A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ. 2007;335:1248–51.Google Scholar
- 26.Tillmann HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int. 2012;32:544–53.Google Scholar
- 27.Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007;45:97–101.Google Scholar
- 28.Price J. An update on hepatitis B, D, and E viruses. Top Antivir Med. 2014;21:157–63.Google Scholar
- 29.Souza LA, Mattos AA, Fiorini M, Ribeiro P, Tovo CV. Clinical outcome of a patient cohort with acute hepatitis B. Clinics (Sao Paulo). 2013;68:718–20.Google Scholar